Boehringer Ingelheim: New vaccine offers triple poultry protection

LinkedIn +

Boehringer Ingelheim’s U.S. Animal Health Business launched a new combined vaccine this week to protect poultry from three highly contagious and life threatening diseases.

  1. Marek’s Disease
  2. IBD – Infectious Bursal Disease (classic and variant types)
  3. Newcastle Disease.

The new vaccine called VAXXITEK® HVT+IBD+ND provides a strong immune foundation and optimized protection against all three.

Historically Boehringer Ingelheim has offered two different vaccines that guard against the these diseases, but they could not be used together. Poultry farmers and veterinarians have had to choose whether to vaccinate against Marek’s Disease and Infectious Bursal Disease (VAXXITEK HVT+IBD) OR Marek’s Disease and Newcastle Disease (NEWXXITEK™ HVT+ND). This new trivalent vaccine solves the issue once and for all.

Nikki Pritchard, global head of poultry vaccines R&D at Boehringer Ingelheim, said VAXXITEK HVT+IBD+ND brings a simplified and effective solution to the poultry industry. “Disease prevention through vaccination is key to ensure better bird health, resulting in bird performance and safety. This is critical in supporting our customer’s ability to produce affordable protein to feed the planet,”.

Boehringer Ingelheim is seeking regulatory approval in several countries to provide its new trivalent vaccine to customers outside the United States. The company will manufacture VAXXITEK HVT+IBD+ND from its site in Gainesville, Georgia, USA, which already produces more than 60 billion doses of poultry vaccine a year for use in the United States and over 60 other countries.

About Boehringer Ingelheim Animal Health USA Inc.

Boehringer Ingelheim Animal Health USA Inc is the second largest animal health business in the world, with net sales of almost $4.7 billion (3.9 billion euros) worldwide in 2018, about 10,000 employees and a presence in more than 150 markets. They have pioneered advancements in vaccines, parasite-control products and therapeutics that limit pain and slow disease, and aim to create the future of animal well-being for pets, horses and livestock by focusing on prevention.

VAXXITEK® is a registered trademark and NEWXXITEK™ is a trademark of Boehringer Ingelheim Animal Health USA Inc. ©2019 Boehringer Ingelheim Animal Health USA Inc., 3239 Satellite Blvd., Duluth, GA 30096. All rights reserved. US-POU-0024-2019

SOURCE Boehringer Ingelheim Animal Health USA Inc.

Share this story:

About Author


Matt has worked in digital publishing for twenty years, holding management positions at Nature ( and William Reed Business Media ( etc.). He has also worked with BBC Worldwide, Centaur Media, UKi Media and Mark Allen Group. Since 2010 Matt has been a digital consultant working with B2B media companies in the agricultural, automotive, aviation, robotics and technology sectors. As Chairman of his local allotment association Matt grows his own food whilst chasing the dream of a one tonne giant pumpkin. He is a member of the British Garden Media Guild and was a finalist in the Garden Media Guild Awards 'blog of the year' category in 2018 and 2019.

Comments are closed.